Pieter Cullis remembers giving a talk at Pfizer in March 2020, just days before Canada implemented stay-at-home measures to curb the deadly COVID-19 pandemic. Five years later, and after the mRNA vaccine technology he worked on found its way into billions of shots, he reflects on the role of nanoparticles in vaccines and how the cancer therapeutics he's helping to develop are next.
